Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination.

Thyroid carcinoma is a common endocrine cancer with a favorable prognosis if subjected to timely treatment. However, the clinical identification of follicular thyroid carcinoma (FTC) among patients with benign thyroid nodules is still a challenge. Preoperative fine needle aspiration-based cytology cannot always differentiate follicular carcinomas from benign follicular neoplasias. Because current methods fail to improve preoperative diagnosis of thyroid nodules, new molecular-based diagnoses should be explored. We conducted a microarray-based study to reveal the genetic profiles unique to FTC and follicular adenomas (FAs), to identify the most parsimonious number of genes that could accurately differentiate between benign and malignant follicular thyroid neoplasia. We confirmed our data by quantitative RT-PCR and immunohistochemistry in two independent validation sets with a total of 114 samples. We were able to identify three genes, cyclin D2 (CCND2), protein convertase 2 (PCSK2), and prostate differentiation factor (PLAB), that allow the accurate molecular classification of FTC and FA. Two independent validation sets revealed that the combination of these three genes could differentiate FTC from FA with a sensitivity of 100%, specificity of 94.7%, and accuracy of 96.7%. In addition, our model allowed the identification of follicular variants of papillary thyroid carcinoma with an accuracy of 85.7%. Three-gene profiling of thyroid nodules can accurately predict the diagnosis of FTC and FA with high sensitivity and specificity, thus identifying promising targets for further investigation to ultimately improve preoperative diagnosis.

[1]  N. Lee,et al.  Silencing of Wnt Signaling and Activation of Multiple Metabolic Pathways in Response to Thyroid Hormone-Stimulated Cell Proliferation , 2001, Molecular and Cellular Biology.

[2]  Grace C H Yang,et al.  Should cytopathologists stop reporting follicular neoplasms on fine‐needle aspiration of the thyroid? , 2003, Cancer.

[3]  G. Brabant,et al.  Identification of a Wnt/β-Catenin Signaling Pathway in Human Thyroid Cells. , 2001, Endocrinology.

[4]  M. Tötsch,et al.  Expression of Galectin-3 in Normal and Malignant Thyroid Tissue by Quantitative PCR and Immunohistochemistry , 2003, Modern Pathology.

[5]  Arie Perry,et al.  Notch1 and Notch2 Have Opposite Effects on Embryonal Brain Tumor Growth , 2004, Cancer Research.

[6]  S. Asa My approach to oncocytic tumours of the thyroid , 2004, Journal of Clinical Pathology.

[7]  F. Iida Thyroid Carcinoma , 1991, Pediatrics In Review.

[8]  Karl Kornacker,et al.  Chipping away at the chip bias: RNA degradation in microarray analysis , 2003, Nature Genetics.

[9]  C. Li,et al.  Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Fagin Perspective: Lessons Learned from Molecular Genetic Studies of Thyroid Cancer-Insights into Pathogenesis and Tumor-Specific Therapeutic Targets. , 2002, Endocrinology.

[11]  M. Niedziela,et al.  Galectin-3 is not an universal marker of malignancy in thyroid nodular disease in children and adolescents. , 2002, The Journal of clinical endocrinology and metabolism.

[12]  N. Seidah,et al.  Inhibition of proprotein convertases enhances cell migration and metastases development of human colon carcinoma cells in a rat model. , 2004, The American journal of pathology.

[13]  G. Fontanini,et al.  Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens. , 2003, Thyroid : official journal of the American Thyroid Association.

[14]  A. Vecchione,et al.  Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions , 2001, The Lancet.

[15]  W H Wong,et al.  Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Jeffrey E. Lee,et al.  Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. , 2003, American journal of surgery.

[17]  D. Segev,et al.  Molecular pathogenesis of thyroid cancer. , 2003, Surgical oncology.

[18]  C. Lohse,et al.  Observer Variation in the Diagnosis of Follicular Variant of Papillary Thyroid Carcinoma , 2004, The American journal of surgical pathology.

[19]  S. Libutti,et al.  Using gene expression profiling to differentiate benign versus malignant thyroid tumors. , 2004, Cancer research.

[20]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  P. V. van Diest,et al.  Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. , 2000, The American journal of pathology.

[22]  H. Gharib,et al.  Nondiagnostic thyroid fine-needle aspiration cytology: management dilemmas. , 2001, Thyroid : official journal of the American Thyroid Association.

[23]  Christian Pilarsky,et al.  WIF1, a component of the Wnt pathway, is down‐regulated in prostate, breast, lung, and bladder cancer , 2003, The Journal of pathology.

[24]  B. Jones,et al.  Analysis of inconclusive fine-needle aspiration of thyroid follicular lesions , 2003, Endocrine pathology.

[25]  C. Barden,et al.  Discrimination of Benign and Malignant Thyroid Nodules by Molecular Profiling , 2004, Annals of surgery.

[26]  C Eng,et al.  Gene expression in papillary thyroid carcinoma reveals highly consistent profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  C. Barden,et al.  Classification of follicular thyroid tumors by molecular signature: results of gene profiling. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  Robert H. Silverman,et al.  Activation of the interferon system by short-interfering RNAs , 2003, Nature Cell Biology.

[29]  V. Vasko,et al.  Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer , 2004, Journal of Medical Genetics.

[30]  M. Welker,et al.  Thyroid nodules. , 2003, American family physician.

[31]  G. Chiappetta,et al.  The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. , 2002, The Journal of clinical endocrinology and metabolism.

[32]  D. Fraker,et al.  The diagnostic dilemma of follicular variant of papillary thyroid carcinoma. , 2003, Surgery.

[33]  S. Liyanarachchi,et al.  Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Y. Takano,et al.  Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis , 1999, The Journal of pathology.

[35]  Charis Eng,et al.  Caveolin-1 and caveolin-2,together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis. , 2003, Cancer research.

[36]  J. Minna,et al.  Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  D. Ross Nonpalpable thyroid nodules--managing an epidemic. , 2002, The Journal of clinical endocrinology and metabolism.

[38]  K. Unsicker,et al.  Growth Differentiation Factor-15 Prevents Low Potassium-induced Cell Death of Cerebellar Granule Neurons by Differential Regulation of Akt and ERK Pathways* , 2003, The Journal of Biological Chemistry.

[39]  J. Shah,et al.  Clinical significance of molecular expression profiles of Hürthle cell tumors of the thyroid gland analyzed via tissue microarrays. , 2002, The American journal of pathology.

[40]  S. Goodman,et al.  Human Telomerase Reverse Transcriptase Gene Expression and the Surgical Management of Suspicious Thyroid Tumors , 2004, Clinical Cancer Research.

[41]  Shinichiro,et al.  Carcinoma , 1906, The Hospital.

[42]  D. Clark,et al.  Beyond the suspicious thyroid fine needle aspirate. A review. , 2003, Acta cytologica.

[43]  Jennifer Shoemaker,et al.  A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. , 2004, The Journal of clinical investigation.

[44]  T. Fahey,et al.  0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(7):3214–3223 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-031811 Molecular Profiling Distinguishes Papillary Carcinoma , 2022 .

[45]  H. Vierhapper,et al.  Risk factors for malignancy of thyroid nodules initially identified as follicular neoplasia by fine-needle aspiration: results of a prospective study of one hundred twenty patients. , 2000, Thyroid : official journal of the American Thyroid Association.

[46]  S. Sukumar,et al.  Human Telomerase Reverse Transcriptase ( hTERT ) Gene Expression in Thyroid Neoplasms 1 , 1999 .

[47]  B. Kinder Well differentiated thyroid cancer , 2003, Current opinion in oncology.

[48]  K. Schmid,et al.  RET rearrangements in archival oxyphilic thyroid tumors: new insights in tumorigenesis and classification of Hürthle cell carcinomas? , 2003, Surgery.

[49]  P. Malfertheiner,et al.  Absence of cyclin D2 expression is associated with promoter hypermethylation in gastric cancer , 2003, British Journal of Cancer.

[50]  C. Plass,et al.  Silencing of the maternally imprinted tumor suppressor ARHI contributes to follicular thyroid carcinogenesis. , 2005, The Journal of clinical endocrinology and metabolism.

[51]  C. Morrison,et al.  Peroxisome proliferator-activated receptor gamma is frequently downregulated in a diversity of sporadic nonmedullary thyroid carcinomas , 2003, Oncogene.

[52]  O. Clark,et al.  False-negative fine-needle aspiration cytology results delay treatment and adversely affect outcome in patients with thyroid carcinoma. , 2004, Thyroid : official journal of the American Thyroid Association.

[53]  P. De Giuli,et al.  Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. , 2001, The Journal of clinical endocrinology and metabolism.

[54]  T. Takano,et al.  High-throughput differential screening of mRNAs by serial analysis of gene expression: decreased expression of trefoil factor 3 mRNA in thyroid follicular carcinomas , 2004, British Journal of Cancer.

[55]  K. Kinzler,et al.  MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.